Sodium Hydroxide → 2-(4-Methyl-6-(2-oxoindolin-6-yl)-2-phenylpyrimidin-5-yl)pentanoic acid
반응식
[CH3:1][C:2]1[C:7]([CH:8]([CH2:13][CH2:14][CH3:15])[C:9]([O:11]C)=[O:10])=[C:6]([C:16]2[CH:24]=[C:23]3[C:19]([CH2:20][C:21](=[O:25])[NH:22]3)=[CH:18][CH:17]=2)[N:5]=[C:4]([C:26]2[CH:31]=[CH:30][CH:29]=[CH:28][CH:27]=2)[N:3]=1.[OH-].[Na+]>CO>[CH3:1][C:2]1[C:7]([CH:8]([CH2:13][CH2:14][CH3:15])[C:9]([OH:11])=[O:10])=[C:6]([C:16]2[CH:24]=[C:23]3[C:19]([CH2:20][C:21](=[O:25])[NH:22]3)=[CH:18][CH:17]=2)[N:5]=[C:4]([C:26]2[CH:31]=[CH:30][CH:29]=[CH:28][CH:27]=2)[N:3]=1참가 물질
4
실험 절차
This compound was prepared according to general method D from methyl 2-(4-methyl-6-(2-oxoindolin-6-yl)-2-phenylpyrimidin-5-yl)pentanoate (0.066 g; 0.159 mmol), sodium hydroxide 10N (0.159 mL; 1.59 mmol) in methanol (1.5 mL). Purification by preparative HPLC (HPLC method 2) furnished 0.0012 g (2%) of the title compound as a white solid.